These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18951343)

  • 1. [Schizophrenia and antipsychotics associated with the metabolic syndrome. An overview].
    Scheepers-Hoeks AM; Wessels-Basten SJ; Scherders MJ; Bravenboer B; Loonen AJ; Kleppe RT; Grouls RJ
    Tijdschr Psychiatr; 2008; 50(10):645-54. PubMed ID: 18951343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schizophrenia, antipsychotics and metabolic disease.
    Reynolds GP
    J Psychopharmacol; 2007 Jun; 21(4):355-6. PubMed ID: 17656424
    [No Abstract]   [Full Text] [Related]  

  • 3. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.
    Barnett AH; Mackin P; Chaudhry I; Farooqi A; Gadsby R; Heald A; Hill J; Millar H; Peveler R; Rees A; Singh V; Taylor D; Vora J; Jones PB
    J Psychopharmacol; 2007 Jun; 21(4):357-73. PubMed ID: 17656425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
    Yogaratnam J; Biswas N; Vadivel R; Jacob R
    East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
    Casey DE; Haupt DW; Newcomer JW; Henderson DC; Sernyak MJ; Davidson M; Lindenmayer JP; Manoukian SV; Banerji MA; Lebovitz HE; Hennekens CH
    J Clin Psychiatry; 2004; 65 Suppl 7():4-18; quiz 19-20. PubMed ID: 15151456
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia.
    Said MA; Sulaiman AH; Habil MH; Das S; Bakar AK; Yusoff RM; Loo TH; Bakar SA
    Singapore Med J; 2012 Dec; 53(12):801-7. PubMed ID: 23268153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metabolic syndrome induced by antipsychotic drugs. The problem of obesity].
    Jufe GS
    Vertex; 2008; 19(82):338-47. PubMed ID: 19424516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antipsychotics and metabolic abnormalities in children and adolescents: a review of the literature and some recommendations].
    Overbeek WA; de Vroede MA; Lahuis BE; Hillegers MH; de Graeff-Meeder ER
    Tijdschr Psychiatr; 2010; 52(5):311-20. PubMed ID: 20458678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies.
    Bou Khalil R
    Clin Neuropharmacol; 2012; 35(3):141-7. PubMed ID: 22592510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic risk factors among medicaid outpatients with schizophrenia receiving second-generation antipsychotics.
    Bell RC; Farmer S; Ries R; Srebnik D
    Psychiatr Serv; 2009 Dec; 60(12):1686-9. PubMed ID: 19952163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions.
    Megna JL; Schwartz TL; Siddiqui UA; Herrera Rojas M
    Ann Clin Psychiatry; 2011 May; 23(2):131-40. PubMed ID: 21547274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics - a retrospective medical records review.
    Wysokiński A; Kowman M; Kłoszewska I
    Psychiatr Danub; 2012 Sep; 24(3):314-22. PubMed ID: 23013638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabolic syndrome in patients with schizophrenia independently from atypical antipsychotics intake].
    Bou Khalil R
    Presse Med; 2012 May; 41(5):e238-43. PubMed ID: 22154487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic syndrome and schizophrenia.
    Meyer JM; Stahl SM
    Acta Psychiatr Scand; 2009 Jan; 119(1):4-14. PubMed ID: 19133915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study.
    Bressington D; Mui J; Tse ML; Gray R; Cheung EF; Chien WT
    BMC Psychiatry; 2016 Nov; 16(1):411. PubMed ID: 27863522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome in patients with psychotic disorders: diagnostic issues, comorbidity and side effects of antipsychotics.
    Kozumplik O; Uzun S; Jakovljević M
    Psychiatr Danub; 2010 Mar; 22(1):69-74. PubMed ID: 20305594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.